A Phase 1 interventional study of GSK4382276A Dose level 1 and GSK4382276A Dose level 2 in Influenza, Human, sponsored by GlaxoSmithKline. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.
Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 83rd largest by enrollment of the 165 interventional ones that give a count, is one of 2 that started in 2022, is one of 22 in phase 1, and was the 177th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 18–64 · Healthy volunteers
GlaxoSmithKline · Sites in United States
Ages 65+ · Healthy volunteers
GlaxoSmithKline · Sites in United States
Ages 65–85
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 56 · Phase 3 74 · Phase 4 12
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 324 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 324 across the 165 interventional studies, 605 across the 22 observational. Of the 178 that completed or were terminated, 132 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
2 of the studies in Influenza, Human by GlaxoSmithKline that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT07464314GlaxoSmithKlineA Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults | 2026-12-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 187 studies in Influenza, Human by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine (GSK4382276A) candidate against influenza in healthy younger adults (YA) and older adults (OA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants of childbearing potential may be enrolled in the study if the participant:
Exclusion Criteria:
Medical conditions
Any clinically significant hematological coagulation or urine analysis laboratory abnormality.
* The investigator should use his/her clinical judgement to decide which abnormalities are clinically significant.
Prior/Concomitant therapy
Administration of a vaccine not foreseen by the study protocol in the period starting 28 days before the study intervention administration, or planned administration within 28 days after the study intervention administration*, with the exception of vaccines authorized or approved for the prevention of COVID-19 (regardless of the type of vaccine).
*In case emergency mass vaccination for an unforeseen public health threat is organized by public health authorities outside the routine immunization program, the time period described above can be reduced to 7 days, if necessary, for that mass vaccination vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, YA adult participants received Flu mRNA at Dose Level 1, the lowest concentration evaluated in the study.
Biological: GSK4382276A Dose level 1
On Day 1, YA participants received Flu mRNA at Dose Level 2, which corresponds to a higher concentration than Dose Level 1.
Biological: GSK4382276A Dose level 2
On Day 1, YA participants received Flu mRNA at Dose Level 3, which corresponds to a higher concentration than Dose Level 2.
Biological: GSK4382276A Dose level 3
On Day 1, YA participants received Flu mRNA at Dose Level 4, which corresponds to a higher concentration than Dose Level 3.
Biological: GSK4382276A Dose level 4
On Day 1, YA participants received Flu mRNA at Dose Level 5, which corresponds to a higher concentration than Dose Level 4.
Biological: GSK4382276A Dose level 5
On Day 1, YA participants received Flu mRNA at Dose Level 6, which corresponds to a higher concentration than Dose Level 5.
Biological: GSK4382276A Dose level 6
On Day 1, YA participants received Flu mRNA at Dose Level 7, which corresponds to a higher concentration than Dose Level 6.
Biological: GSK4382276A Dose level 7
On Day 1, YA participants received Flu mRNA at Dose Level 8, which corresponds to a higher concentration than Dose Level 7.
Biological: GSK4382276A Dose level 8
On Day 1, YA participants received Flu mRNA at Dose Level 9, which corresponds to a higher concentration than Dose Level 8.
Biological: GSK4382276A Dose level 9
On Day 1, YA participants received Flu mRNA at Dose Level 10, the highest concentration evaluated in the study.
Biological: GSK4382276A Dose level 10
On Day 1, YA participants received a single dose of FDQ21A - NH or FDQ22A -NH administered as a control and were analyzed together as pooled group throughout the study.
Combination Product: FDQ21A-NH · Combination Product: FDQ22A-NH
On Day 1, OA participants received Flu mRNA at Dose Level 7.
Biological: GSK4382276A Dose level 7
On Day 1, OA participants received a single dose of FDQ21A-NH administered at as a control.
Combination Product: FDQ21A-NH
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Also known as: Flu mRNA
Single dose of intervention administered at Day 1
Single dose of intervention administered at Day 1
Number of Participants Reporting Any Solicited Administration Site Events
Assessed solicited administration site events included pain, erythema/redness, swelling and Lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade.
Time frame: Day 1 to Day 7
Number of Participants Reporting Any Solicited Systemic Events
Assessed solicited systemic events included fever, chills, headache, myalgia, arthralgia and fatigue. Any = occurrence of the symptom regardless of intensity grade.
Time frame: Day 1 to Day 7
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)
An unsolicited AEs is an AEs that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs must have been communicated by a participant who has signed the informed consent or through his/her caregiver. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade or relation to study vaccination.
Time frame: Day 1 to Day 28
Number of Participants Reporting Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or resulted in abnormal pregnancy outcomes, or in other situations that were considered serious per medical or scientific judgment.
Time frame: Day 1 to Day 183
Number of Participants Reporting AEs of Special Interest (AESIs)
The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs).
Time frame: Day 1 to Day 183
Number of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, Clinical Chemistry, Coagulation and Urine Analysis
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.
Time frame: At Day 8 compared to baseline (Day 1)
Number of Participants Reporting Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology,Clinical Chemistry, Coagulation and Urine Analysis
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.
Time frame: At Day 29 compared to baseline (Day 1)
Geometric Mean Titers (GMT) of Anti-vaccine Antibody Titers
Time frame: At Day 1
GMT of Anti-vaccine Antibody Titers
Time frame: At Day 22
Geometric Mean Increase (GMI) of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 22
GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titers over the Day 1 anti-vaccine antibody titers.
Time frame: From Day 1 to Day 22
Percentage of Participants With Anti-vaccine Antibody Seroconversion Rate (SCR)
SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer ≥ 1:40 or a pre-dose anti-vaccine antibody titer ≥ 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer.
Time frame: From Day 1 to Day 22
Percentage of Participants With Anti-vaccine Antibody Seroprotection Rate (SPR)
SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer ≥ 1:40.
Time frame: At Day 22
GMT of Anti-vaccine Antibody Titers
Time frame: At Day 62 and Day 183
GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 62
GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titer over the Day 1 anti-vaccine antibody titer.
Time frame: From Day 1 to Day 62
GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 183
GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titer over the Day 1 anti-vaccine antibody titer.
Time frame: From Day 1 to Day 183
Percentage of Participants With Anti-vaccine Antibody SPR
SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titers ≥ 1:40.
Time frame: At Day 62 and Day 183
| Milestone | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 25 | 24 | 35 | 32 | 16 |
| Completed | 24 | 24 | 24 | 24 | 24 | 24 | 22 | 24 | 25 | 23 | 35 | 32 | 16 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
Assessed solicited administration site events included pain, erythema/redness, swelling and Lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade.
| Participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 6 | 0 | 1 | 0 |
| Pain | 5 | 6 | 8 | 14 | 16 | 19 | 21 | 21 | 25 | 24 | 25 | 14 | 7 |
| Swelling | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 5 | 6 | 0 | 4 | 0 |
| Lymphadenopathy | 0 | 1 | 4 | 3 | 5 | 4 | 7 | 9 | 9 | 12 | 9 | 0 | 0 |
Assessed solicited systemic events included fever, chills, headache, myalgia, arthralgia and fatigue. Any = occurrence of the symptom regardless of intensity grade.
| Participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arthralgia | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 7 | 6 | 15 | 4 | 2 | 2 |
| Chills | 1 | 0 | 0 | 2 | 3 | 4 | 9 | 4 | 14 | 10 | 1 | 2 | 0 |
| Fatigue | 8 | 8 | 12 | 9 | 12 | 11 | 16 | 15 | 22 | 22 | 19 | 6 | 2 |
| Headache | 11 | 6 | 4 | 9 | 7 | 9 | 14 | 12 | 19 | 19 | 13 | 12 | 4 |
| Myalgia | 2 | 3 | 4 | 5 | 4 | 5 | 15 | 13 | 20 | 20 | 13 | 5 | 1 |
| Fever | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 8 | 2 | 1 | 0 |
An unsolicited AEs is an AEs that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs must have been communicated by a participant who has signed the informed consent or through his/her caregiver. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade or relation to study vaccination.
| Participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Any Unsolicited Adverse Events (AEs) | 13 | 13 | 14 | 17 | 13 | 16 | 12 | 16 | 15 | 13 | 24 | 14 | 8 |
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or resulted in abnormal pregnancy outcomes, or in other situations that were considered serious per medical or scientific judgment.
| Participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Serious Adverse Events (SAEs) | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs).
| Participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Reporting AEs of Special Interest (AESIs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.
| Participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abnormal non-significant to clinically significant | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Normal or missing to clinically significant | 0 | 2 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 1 |
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. Normal or missing values refer to laboratory values that were within normal range or missing at baseline.
| Participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abnormal non-significant to clinically significant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Normal or missing to clinically significant | 3 | 0 | 0 | 2 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Titers | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geometric Mean Titers (GMT) of Anti-vaccine Antibody Titers | 29.59 (16.05 to 54.56) | 53.97 (28.15 to 103.48) | 31.43 (17.67 to 55.91) | 28.67 (15.56 to 52.82) | 16.33 (9.58 to 27.84) | 16.33 (9.82 to 27.16) | 43.78 (22.19 to 86.38) | 21.23 (12.15 to 37.11) | 41.78 (22.90 to 76.26) | 54.14 (31.83 to 92.06) | 30.07 (17.46 to 51.78) | 38.65 (25.05 to 59.63) | 40.82 (19.90 to 83.75) |
| Titers | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GMT of Anti-vaccine Antibody Titers | 269.00 (120.50 to 600.47) | 314.88 (139.83 to 709.07) | 420.90 (191.00 to 927.55) | 436.90 (198.46 to 961.79) | 509.49 (228.62 to 1135.46) | 574.09 (258.11 to 1276.91) | 1144.59 (520.12 to 2518.84) | 655.57 (308.11 to 1394.83) | 1124.85 (568.42 to 2226.00) | 923.79 (427.53 to 1996.07) | 313.07 (151.79 to 645.71) | 571.29 (384.74 to 848.30) | 245.66 (159.33 to 378.76) |
GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titers over the Day 1 anti-vaccine antibody titers.
| Ratio | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geometric Mean Increase (GMI) of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 22 | 8.62 (3.86 to 19.24) | 10.09 (4.48 to 22.72) | 13.49 (6.12 to 29.73) | 14.00 (6.36 to 30.82) | 16.33 (7.33 to 36.39) | 18.40 (8.27 to 40.92) | 36.68 (16.67 to 80.72) | 21.01 (9.87 to 44.70) | 36.05 (18.22 to 71.34) | 29.61 (13.70 to 63.97) | 10.03 (4.86 to 20.69) | 14.50 (9.76 to 21.53) | 6.23 (4.04 to 9.61) |
SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer ≥ 1:40 or a pre-dose anti-vaccine antibody titer ≥ 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer.
| Percentage of participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Anti-vaccine Antibody Seroconversion Rate (SCR) | 47.8 (26.8 to 69.4) | 50.0 (28.2 to 71.8) | 82.6 (61.2 to 95.0) | 78.3 (56.3 to 92.5) | 95.7 (78.1 to 99.9) | 95.8 (78.9 to 99.9) | 87.0 (66.4 to 97.2) | 95.7 (78.1 to 99.9) | 95.8 (78.9 to 99.9) | 95.8 (78.9 to 99.9) | 59.4 (40.6 to 76.3) | 89.7 (72.6 to 97.8) | 56.3 (29.9 to 80.2) |
SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer ≥ 1:40.
| Percentage of participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Anti-vaccine Antibody Seroprotection Rate (SPR) | 95.7 (78.1 to 99.9) | 100 (84.6 to 100) | 100 (85.2 to 100) | 100 (85.2 to 100) | 100 (85.2 to 100) | 100 (85.8 to 100) | 100 (85.2 to 100) | 100 (85.2 to 100) | 100 (85.8 to 100) | 100 (85.8 to 100) | 100 (89.1 to 100) | 96.6 (82.2 to 99.9) | 93.8 (69.8 to 99.8) |
| Titers | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Post-dosing at Day 62 | 180.49 (81.00 to 402.16) | 165.29 (73.19 to 373.31) | 253.76 (116.06 to 554.84) | 325.51 (147.74 to 717.15) | 315.22 (143.52 to 692.32) | 315.45 (143.12 to 695.29) | 585.92 (254.77 to 1347.50) | 340.76 (162.66 to 713.89) | 703.32 (363.72 to 1360.01) | — | 223.85 (106.67 to 469.74) | 304.72 (183.75 to 505.31) | 193.62 (108.73 to 344.78) |
| Post-dosing at Day 183 | 139.93 (59.67 to 328.15) | 119.60 (50.66 to 282.35) | 183.46 (78.33 to 429.70) | 200.75 (86.89 to 463.83) | 173.18 (76.23 to 393.40) | 206.82 (91.11 to 469.51) | 202.41 (77.59 to 527.99) | 208.90 (95.63 to 456.32) | 307.75 (154.52 to 612.91) | — | 192.15 (88.73 to 416.14) | 158.15 (82.85 to 301.90) | 122.32 (48.12 to 310.94) |
GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titer over the Day 1 anti-vaccine antibody titer.
| Ratio | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 62 | 6.87 (3.08 to 15.32) | 6.29 (2.79 to 14.22) | 9.66 (4.42 to 21.13) | 12.40 (5.63 to 27.31) | 12.00 (5.47 to 26.36) | 12.01 (5.45 to 26.48) | 22.31 (9.70 to 51.31) | 12.98 (6.19 to 27.19) | 26.78 (13.85 to 51.79) | — | 8.52 (4.06 to 17.89) | 8.05 (4.85 to 13.34) | 5.11 (2.87 to 9.10) |
GMI is defined as the geometric mean of the ratios of the post-dose anti-vaccine antibody titer over the Day 1 anti-vaccine antibody titer.
| Ratio | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GMI of Anti-vaccine Antibody Titers From Day 1 (Baseline) to Day 183 | 6.35 (2.71 to 14.90) | 5.43 (2.30 to 12.82) | 8.33 (3.56 to 19.51) | 9.12 (3.95 to 21.06) | 7.86 (3.46 to 17.87) | 9.39 (4.14 to 21.32) | 9.19 (3.52 to 23.98) | 9.49 (4.34 to 20.72) | 13.98 (7.02 to 27.83) | — | 8.73 (4.03 to 18.90) | 3.73 (1.95 to 7.12) | 2.88 (1.13 to 7.33) |
SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titers ≥ 1:40.
| Percentage of participants | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Post-dosing at Day 62 | 95.2 (76.2 to 99.9) | 100 (82.4 to 100) | 100 (85.2 to 100) | 100 (83.9 to 100) | 95.8 (78.9 to 99.9) | 100 (85.8 to 100) | 100 (76.8 to 100) | 100 (80.5 to 100) | 100 (83.2 to 100) | — | 100 (85.2 to 100) | 93.3 (68.1 to 99.8) | 90.0 (55.5 to 99.7) |
| Post-dosing at Day 183 | 88.2 (63.6 to 98.5) | 94.1 (71.3 to 99.9) | 100 (79.4 to 100) | 100 (80.5 to 100) | 91.3 (72.0 to 98.9) | 91.7 (73.0 to 99.0) | 100 (63.1 to 100) | 100 (78.2 to 100) | 100 (83.2 to 100) | — | 94.7 (74.0 to 99.9) | 83.3 (51.6 to 97.9) | 100 (54.1 to 100) |
Collected over Solicited AEs: during the 7-day follow-up period after vaccination. Unsolicited AEs: during the 28-day follow-up period after vaccination. All-cause mortality, SAEs and AESIs: from first vaccination (Day 1) up to study end (Day 183). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Flu mRNA_Dose Level 1_Younger Adults (YA) | 0/24 (0%) | 1/24 (4.2%) | 17/24 (70.8%) |
| Flu mRNA_Dose Level 2 _YA | 0/24 (0%) | 0/24 (0%) | 20/24 (83.3%) |
| Flu mRNA_Dose Level 3_YA | 0/24 (0%) | 0/24 (0%) | 21/24 (87.5%) |
| Flu mRNA_Dose Level 4_YA | 0/24 (0%) | 0/24 (0%) | 19/24 (79.2%) |
| Flu mRNA_Dose Level 5_YA | 0/24 (0%) | 2/24 (8.3%) | 22/24 (91.7%) |
| Flu mRNA_Dose Level 6_YA | 0/24 (0%) | 0/24 (0%) | 24/24 (100%) |
| Flu mRNA_Dose Level 7_YA | 0/24 (0%) | 0/24 (0%) | 23/24 (95.8%) |
| Flu mRNA_ Dose Level 8_YA | 0/24 (0%) | 0/24 (0%) | 23/24 (95.8%) |
| Flu mRNA_Dose Level 9_YA | 0/25 (0%) | 0/25 (0%) | 25/25 (100%) |
| Flu mRNA_Dose Level 10_YA | 0/24 (0%) | 0/24 (0%) | 24/24 (100%) |
| Pooled Control_YA | 0/35 (0%) | 1/35 (2.9%) | 32/35 (91.4%) |
| Flu mRNA_Dose Level 7_Older Adults (OA) | 0/32 (0%) | 1/32 (3.1%) | 24/32 (75%) |
| Control_OA | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| Event | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Craniofacial fractureInjury, poisoning and procedural complications | 1/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/25 | 0/24 | 0/35 | 0/32 | 0/16 |
| Poisoning deliberateInjury, poisoning and procedural complications | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 0/25 | 0/24 | 0/35 | 0/32 | 0/16 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 0/25 | 0/24 | 0/35 | 0/32 | 0/16 |
| Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 0/25 | 0/24 | 0/35 | 0/32 | 0/16 |
| Abdominal infectionInfections and infestations | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/25 | 0/24 | 0/35 | 1/32 | 0/16 |
| DepressionPsychiatric disorders | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/25 | 0/24 | 1/35 | 0/32 | 0/16 |
| Event | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Administration site painGeneral disorders | 5/24 | 6/24 | 8/24 | 14/24 | 16/24 | 19/24 | 21/24 | 21/24 | 25/25 | 24/24 | 25/35 | 14/32 | 7/16 |
| FatigueGeneral disorders | 8/24 | 8/24 | 12/24 | 10/24 | 12/24 | 11/24 | 16/24 | 15/24 | 22/25 | 22/24 | 20/35 | 7/32 | 2/16 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/24 | 3/24 | 4/24 | 5/24 | 5/24 | 6/24 | 15/24 | 13/24 | 20/25 | 20/24 | 13/35 | 7/32 | 1/16 |
| HeadacheNervous system disorders | 11/24 | 8/24 | 8/24 | 10/24 | 9/24 | 11/24 | 14/24 | 13/24 | 19/25 | 19/24 | 17/35 | 12/32 | 5/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/24 | 2/24 | 3/24 | 3/24 | 3/24 | 4/24 | 4/24 | 8/24 | 6/25 | 15/24 | 4/35 | 4/32 | 3/16 |
| ChillsGeneral disorders | 1/24 | 0/24 | 0/24 | 2/24 | 3/24 | 4/24 | 9/24 | 4/24 | 14/25 | 10/24 | 1/35 | 3/32 | 0/16 |
| LymphadenopathyBlood and lymphatic system disorders | 0/24 | 1/24 | 4/24 | 3/24 | 5/24 | 4/24 | 7/24 | 9/24 | 9/25 | 12/24 | 10/35 | 0/32 | 0/16 |
| PyrexiaGeneral disorders | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 0/24 | 2/24 | 2/25 | 8/24 | 2/35 | 1/32 | 0/16 |
| Administration site erythemaGeneral disorders | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 2/24 | 3/25 | 6/24 | 0/35 | 1/32 | 0/16 |
| Administration site swellingGeneral disorders | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 2/24 | 5/25 | 6/24 | 0/35 | 4/32 | 0/16 |
| Age, Continuous(Years) | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YA | 30.2 ± 8.5 | 32.5 ± 7.6 | 34.6 ± 7.3 | 35.7 ± 7.8 | 30.5 ± 9.5 | 30.7 ± 8.1 | 29.8 ± 7.6 | 35.8 ± 7.1 | 27.8 ± 5.7 | 29.1 ± 5.8 | 32.0 ± 7.8 | — | — | 31.7 ± 7.9 |
| OA | — | — | — | — | — | — | — | — | — | — | — | 66.8 ± 4.1 | 67.9 ± 4.6 | 67.2 ± 4.3 |
| Sex: Female, Male(Participants) | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 17 | 16 | 11 | 15 | 15 | 11 | 15 | 14 | 20 | 11 | 22 | 20 | 5 | 192 |
| Male | 7 | 8 | 13 | 9 | 9 | 13 | 9 | 10 | 5 | 13 | 13 | 12 | 11 | 132 |
| Race/Ethnicity, Customized(Participants) | Flu mRNA_Dose Level 1_Younger Adults (YA) | Flu mRNA_Dose Level 2 _YA | Flu mRNA_Dose Level 3_YA | Flu mRNA_Dose Level 4_YA | Flu mRNA_Dose Level 5_YA | Flu mRNA_Dose Level 6_YA | Flu mRNA_Dose Level 7_YA | Flu mRNA_ Dose Level 8_YA | Flu mRNA_Dose Level 9_YA | Flu mRNA_Dose Level 10_YA | Pooled Control_YA | Flu mRNA_Dose Level 7_Older Adults (OA) | Control_OA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 4 |
| White | 24 | 24 | 23 | 24 | 24 | 22 | 24 | 24 | 21 | 24 | 35 | 32 | 15 | 316 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Aug 2022 to primary completion in Mar 2024, 19 months.
Results were first posted in Mar 2026, 1 year 11 months after primary completion.
Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 19 months is above that.
Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.